BOLD THERAPEUTICS

Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a ruthenium-based small molecule therapeutic, improves the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and proliferation pathway. Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.